BCL2L1 and triple-negative breast carcinoma: This implies that the paracrine effects of paclitaxel will be overtly letal provided BCL-xL expression in cancer cells is relatively low, a feature that was associated with sensitivity to chemotherapy in triple negative breast cancers (TNBC)37.